Marker Therapeutics Inc (NAS:MRKR)

$ 3.6399 -0.3901 (-9.68%) Market Cap: 32.47 Mil Enterprise Value: 17.13 Mil PE Ratio: 0 PB Ratio: 2.76 GF Score: 40/100

Marker Therapeutics Inc to Participate in the Beyond CAR-T: What's Next for Cell Therapy Event Transcript
Aug 09, 2023
Marker Therapeutics Inc to Host Clinical Program Update Call Transcript
Feb 16, 2022
Marker Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Jun 21, 2021
Q1 2021 Marker Therapeutics Inc Earnings Call Transcript
May 12, 2021

$21.6 (-8.47%)

Earnings
Q3 2020 Marker Therapeutics Inc Earnings Call Transcript
Nov 09, 2020

$14.9 (+2.76%)

Earnings
Marker Therapeutics Inc MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting Transcript
Jun 01, 2020
Q1 2020 Marker Therapeutics Inc Earnings Call Transcript
May 11, 2020

$24.8 (+3.12%)

Earnings
Q3 2019 Marker Therapeutics Inc Earnings Call Transcript
Nov 12, 2019

$39.2 (-2.00%)

Earnings
Marker Therapeutics Inc Special Call Transcript
Jul 22, 2019
Marker Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference Transcript
May 16, 2019

Marker Therapeutics Inc MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting Transcript

Jun 01, 2020 / 12:00PM GMT

Release Date Price: $21.6 (-4.85%)

Transcript

Operator

Good morning, ladies and gentlemen, and welcome to Marker Therapeutics Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the call over to Mr. Tony Kim, Chief Financial Officer at Marker. Please go ahead.

Anthony H. Kim

Marker Therapeutics, Inc. - CFO

Thanks, and welcome, everyone. The press release containing the interim study results with our MultiTAA-specific T cell therapy in pancreatic cancer, as reported during the ASCO annual meeting late last week, are available in the News section of the Marker Therapeutics website.

Joining me for the call today are Peter Hoang, our Chief Executive Officer; Dr. Mythili Koneru, our Chief Medical Officer; and Dr. Brandon Smaglo, Lead Investigator for the TACTOPS trial. Dr. Smaglo is currently Associate Professor in the Department of Gastrointestinal Medical Oncology in the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston, Texas, and was formerly at the Baylor College of Medicine where he led the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.